Product Details
Product Details
Product Specification
Species | Human |
Synonyms | CD79B, B29, AGM6, IGB |
Accession | P40259 |
Amino Acid Sequence | Ala29-Asp159, with C-terminal Human IgG1 Fc |
Expression System | HEK293 |
Molecular Weight | 50-60kDa |
Purity | >95% by SDS-PAGE |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Tag | Human Fc Tag |
Physical Appearance | Lyophilized Powder |
Storage Buffer | PBS, pH7.4 |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
Reference | 1、Duncan L. et al. 2010 Molecular characterisation of the CD79a and CD79b subunits of the B cell receptor complex in the gray short-tailed opossum (Monodelphis domestica) and tammar wallaby (Macropus eugenii): Delayed B cell immunocompetence in marsupial neonates. Vet Immunol Immunopathol. 136: 235-247. |
Background
CD79, the signaling component of the B-cell receptor (BCR), is a promising target of antibodies and ADCs for the treatment of B-cell malignancies and autoimmune diseases. CD79 is a heterodimer, consisting of CD79a and CD79b, and is an attractive target because it is B cell specific and is expressed in almost all forms of non-Hodgkin's lymphoma and most forms of chronic lymphocytic leukemia. CD79 is particularly attractive for use as an ADC because the receptor is trafficked to a lysosome-like compartment as part of antigen presentation, thereby providing a mechanism for enhancing the release of drug from the ADC
Picture
Picture
SDS-PAGE

ELISA

Immobilized CD79B Fc Chimera, Human (Cat. No. UA010240) at 2.0μg/mL (100μL/well) can bind Biotinylated Anti-Human CD79b (Polatuzumab) with EC50 of 1.59-2.29ng/mL.

